Drugs / V330
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06630117 | Mar 2024 → Oct 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06630117 ↗ |
| Modality | Vaccine | “a new vaccine, V330” NCT06630117 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06630117 ↗ |